These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 8132722)

  • 1. Cholesterol levels in young adults: screen and intervene?
    Gotto AM
    Hosp Pract (Off Ed); 1994 Mar; 29(3):109-10, 115-6. PubMed ID: 8132722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholesterol and the older adult.
    Kaiser FE
    South Med J; 1993 Oct; 86(10):2S11-4. PubMed ID: 8211350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of cholesterol on cardiovascular morbidity and mortality in older adults.
    Chen YT; Krumholz HM
    Nutrition; 1999 Mar; 15(3):242-4. PubMed ID: 10198923
    [No Abstract]   [Full Text] [Related]  

  • 4. Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy.
    Jetty V; Glueck CJ; Lee K; Goldenberg N; Prince M; Kumar A; Goldenberg M; Anand I; Wang P
    Vasc Health Risk Manag; 2017; 13():247-253. PubMed ID: 28740397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of high blood cholesterol.
    Smith MD; McGhan WF
    Bus Health; 1996 Apr; 14(4):67-8, 70, 72-4. PubMed ID: 10157682
    [No Abstract]   [Full Text] [Related]  

  • 6. [Limitations of interventions against hypercholesterolemia].
    Ripoll MA
    Aten Primaria; 1996 Mar; 17(4):305-6. PubMed ID: 8679872
    [No Abstract]   [Full Text] [Related]  

  • 7. Heartsick America.
    Cowley G
    Newsweek; 2001 May; 137(22):43. PubMed ID: 11393041
    [No Abstract]   [Full Text] [Related]  

  • 8. Lipid-modifying therapy and attainment of cholesterol goals in Hungary: the return on expenditure achieved for lipid therapy (REALITY) study.
    Paragh G; Márk L; Zámolyi K; Pados G; Ofner P
    Clin Drug Investig; 2007; 27(9):647-60. PubMed ID: 17705573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bridging the treatment gap.
    Smith SC
    Am J Cardiol; 2000 Jun; 85(12A):3E-7E. PubMed ID: 10858487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Annual influenza immunization: as important as control of blood pressure and cholesterol as secondary prevention for cardiovascular disease.
    Grajewski J; Slusar M; Hayney MS
    J Am Pharm Assoc (2003); 2007; 47(5):662-3. PubMed ID: 17848356
    [No Abstract]   [Full Text] [Related]  

  • 11. IMPROVE-IT clinical implications. Should the "high-intensity cholesterol-lowering therapy" strategy replace the "high-intensity statin therapy"?
    Masana L; Pedro-Botet J; Civeira F
    Atherosclerosis; 2015 May; 240(1):161-2. PubMed ID: 25795557
    [No Abstract]   [Full Text] [Related]  

  • 12. Lipid-Lowering Therapies: Risks in Women and Evidence-Based Options.
    Shah T; Virani SS
    Tex Heart Inst J; 2018 Aug; 45(4):238-239. PubMed ID: 30374235
    [No Abstract]   [Full Text] [Related]  

  • 13. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.
    Agabiti Rosei E; Salvetti M
    High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):217-30. PubMed ID: 27567901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Treatment of High Cholesterol Levels: Effectiveness and Value.
    Tice JA; Kazi DS; Pearson SD
    JAMA Intern Med; 2016 Jan; 176(1):107-8. PubMed ID: 26662572
    [No Abstract]   [Full Text] [Related]  

  • 15. Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population.
    Pharoah PD; Hollingworth W
    BMJ; 1996 Jun; 312(7044):1443-8. PubMed ID: 8664620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The evolution of European guidelines: changing the management of cholesterol levels.
    Erhardt LR; Gotto A
    Atherosclerosis; 2006 Mar; 185(1):12-20. PubMed ID: 16309687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of cholesterol abnormalities.
    Lockman AR; Tribastone AD; Knight KV; Franko JP
    Am Fam Physician; 2005 Mar; 71(6):1137-42. PubMed ID: 15791891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hypercholesterolemia-related cardiovascular risk: a continuum from a notion of normality, intervention threshold and therapeutic objectives].
    Scheen AJ
    Rev Med Liege; 1999 Jan; 54(1):17-21. PubMed ID: 10081305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States.
    Gandra SR; Villa G; Fonarow GC; Lothgren M; Lindgren P; Somaratne R; van Hout B
    Clin Cardiol; 2016 Jun; 39(6):313-20. PubMed ID: 27092712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modest interventions deliver significant results in cholesterol management.
    Dis Manag Advis; 2002 Nov; 8(11):173-5, 161. PubMed ID: 12506458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.